Publications by authors named "Ajaykumar Rao"
Background: Emerging data suggest that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve kidney outcomes for people with type 2 diabetes (T2D). Direct comparisons of the kidney and cardiovascular effectiveness of GLP-1 RA with sodium-glucose cotransporter 2 inhibitors (SGLT2i), a first-line therapy for this population, are needed.
Objectives: The authors compared kidney and cardiovascular outcomes for new users of SGLT2i and GLP-1 RAs with T2D.
Importance: Chronic kidney disease (CKD) is an often-asymptomatic complication of type 2 diabetes (T2D) that requires annual screening to diagnose. Patient-level factors linked to inadequate screening and treatment can inform implementation strategies to facilitate guideline-recommended CKD care.
Objective: To identify risk factors for nonconcordance with guideline-recommended CKD screening and treatment in patients with T2D.
Article Synopsis
- Empagliflozin, a sodium-glucose co-transporter-2 inhibitor, shows greater kidney and cardiovascular benefits compared to dipeptidyl peptidase-4 inhibitors (DPP4is) in patients with type 2 diabetes and chronic kidney disease (CKD), based on real-world health data.
- In a study involving over 62,000 patients, those starting empagliflozin had a 25% lower risk of major kidney outcomes and reduced risks for mortality and cardiovascular events compared to those taking DPP4is.
- While empagliflozin was more effective, it did have a higher incidence of genital infections, but this did not significantly affect the overall safety profile.
Unlabelled: Mineralocorticoid Receptor (MR) activation is involved in blood pressure regulation and the pathogenesis of cardiovascular diseases, such as cardiac fibrosis, vascular inflammation and arterial aging. Recent investigations suggest a role for MR activation in metabolic dysregulation.
Objective: To test the effect of MR blockade on basal and postprandial glucose and lipid levels after a meal high in fat and glucose in healthy males.